{"title":"土耳其2型糖尿病患者目前的治疗方法和血糖控制：来自土耳其一家三级医院的真实证据","authors":"S B Demir, A Yesilova, M Cengiz, M Adas","doi":"10.4183/aeb.2024.324","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study examined the glycemic control among adult patients with type 2 diabetes mellitus (T2DM) and their ongoing antidiabetic therapy focusing on potential differences in attaintment of glycemic control associated with the use of specific antidiabetic regimens (ADR).</p><p><strong>Design: </strong>This was a cross sectional study conducted between September 2019 and March 2020 at a tertiary hospital, department of Internal Medicine.</p><p><strong>Subjects and methods: </strong>Patients with T2DM who had a diagnosis of T2DM for at least one year and used their prescribed ADR for at least 3 months were included in the study. Glycated hemoglobin (HbA1c) was used for evaluation of glycemic control.</p><p><strong>Results: </strong>A total of 500 patients aged 59.4 (±10.2) years, with 9.9 (±6.7) years of diabetes duration (54% women, BMI: 29.6±5.1kg/m<sup>2</sup>) were analysed. The mean HbA1c was 8.3% (±1.9) and 34.2% of patients had a HbA1c level ≤7 %. 12%, 20% and 15.4% of diabetic patients were prescribed one, two or more than three antidiabetic drugs, 6.4% were on glucagon-like peptide 1 receptor agonists (GLP-1RA) only and 46% received insulin. Education level (OR=0.79; 95 % CI 0.66-0.94 p=0.009) and use of GLP-1RA (OR=0.19; 95 % CI 0.07-0.51 p=0.001) were associated with improved glycemic control while longer diabetes duration (OR=1.06; 95 % CI 1.02-1.11 p=0.004), use of basal insulin (OR=2.91; 95 % CI 1.70-6.88 p=0.010) and basal-prandial regiments (OR=2.49; CI 1.54-5.38 p=0.020) were associated with HbA1c >7%.</p><p><strong>Conclusions: </strong>Despite the introduction of novel drugs in the treatment of T2DM a majority of our patients fail to reach therapeutic goals.</p>","PeriodicalId":50902,"journal":{"name":"Acta Endocrinologica-Bucharest","volume":"20 3","pages":"324-333"},"PeriodicalIF":0.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169838/pdf/","citationCount":"0","resultStr":"{\"title\":\"CURRENT TREATMENT APPROACHES AND GLYCEMIC CONTROL IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD EVIDENCE FROM A TERTIARY HOSPITAL IN TURKEY.\",\"authors\":\"S B Demir, A Yesilova, M Cengiz, M Adas\",\"doi\":\"10.4183/aeb.2024.324\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study examined the glycemic control among adult patients with type 2 diabetes mellitus (T2DM) and their ongoing antidiabetic therapy focusing on potential differences in attaintment of glycemic control associated with the use of specific antidiabetic regimens (ADR).</p><p><strong>Design: </strong>This was a cross sectional study conducted between September 2019 and March 2020 at a tertiary hospital, department of Internal Medicine.</p><p><strong>Subjects and methods: </strong>Patients with T2DM who had a diagnosis of T2DM for at least one year and used their prescribed ADR for at least 3 months were included in the study. Glycated hemoglobin (HbA1c) was used for evaluation of glycemic control.</p><p><strong>Results: </strong>A total of 500 patients aged 59.4 (±10.2) years, with 9.9 (±6.7) years of diabetes duration (54% women, BMI: 29.6±5.1kg/m<sup>2</sup>) were analysed. The mean HbA1c was 8.3% (±1.9) and 34.2% of patients had a HbA1c level ≤7 %. 12%, 20% and 15.4% of diabetic patients were prescribed one, two or more than three antidiabetic drugs, 6.4% were on glucagon-like peptide 1 receptor agonists (GLP-1RA) only and 46% received insulin. Education level (OR=0.79; 95 % CI 0.66-0.94 p=0.009) and use of GLP-1RA (OR=0.19; 95 % CI 0.07-0.51 p=0.001) were associated with improved glycemic control while longer diabetes duration (OR=1.06; 95 % CI 1.02-1.11 p=0.004), use of basal insulin (OR=2.91; 95 % CI 1.70-6.88 p=0.010) and basal-prandial regiments (OR=2.49; CI 1.54-5.38 p=0.020) were associated with HbA1c >7%.</p><p><strong>Conclusions: </strong>Despite the introduction of novel drugs in the treatment of T2DM a majority of our patients fail to reach therapeutic goals.</p>\",\"PeriodicalId\":50902,\"journal\":{\"name\":\"Acta Endocrinologica-Bucharest\",\"volume\":\"20 3\",\"pages\":\"324-333\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169838/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Endocrinologica-Bucharest\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4183/aeb.2024.324\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Endocrinologica-Bucharest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4183/aeb.2024.324","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的：本研究考察了2型糖尿病（T2DM）成人患者的血糖控制情况及其持续的降糖治疗，重点关注与使用特定降糖方案（ADR）相关的血糖控制实现的潜在差异。设计：这是一项横断面研究，于2019年9月至2020年3月在一家三级医院内科进行。研究对象和方法：诊断为T2DM的患者至少1年，且使用处方不良反应至少3个月的T2DM患者被纳入研究。糖化血红蛋白（HbA1c）用于评估血糖控制情况。结果：共分析500例患者，年龄59.4（±10.2）岁，糖尿病病程9.9（±6.7）年（女性54%，BMI: 29.6±5.1kg/m2）。平均HbA1c为8.3%（±1.9），34.2%的患者HbA1c≤7%。12%、20%和15.4%的糖尿病患者使用一种、两种或三种以上的降糖药，6.4%的患者仅使用胰高血糖素样肽1受体激动剂（GLP-1RA）， 46%的患者使用胰岛素。教育程度(OR=0.79；95% CI 0.66-0.94 p=0.009)和GLP-1RA的使用(OR=0.19；95% CI 0.07-0.51 p=0.001)与血糖控制改善相关，而糖尿病持续时间较长(OR=1.06；95% CI 1.02-1.11 p=0.004)，使用基础胰岛素(OR=2.91；95% CI 1.70-6.88 p=0.010)和基础膳食组(OR=2.49；CI 1.54 ~ 5.38 p=0.020)与HbA1c bb0.7%相关。结论：尽管在T2DM治疗中引入了新药，但大多数患者未能达到治疗目标。
CURRENT TREATMENT APPROACHES AND GLYCEMIC CONTROL IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD EVIDENCE FROM A TERTIARY HOSPITAL IN TURKEY.
Objective: This study examined the glycemic control among adult patients with type 2 diabetes mellitus (T2DM) and their ongoing antidiabetic therapy focusing on potential differences in attaintment of glycemic control associated with the use of specific antidiabetic regimens (ADR).
Design: This was a cross sectional study conducted between September 2019 and March 2020 at a tertiary hospital, department of Internal Medicine.
Subjects and methods: Patients with T2DM who had a diagnosis of T2DM for at least one year and used their prescribed ADR for at least 3 months were included in the study. Glycated hemoglobin (HbA1c) was used for evaluation of glycemic control.
Results: A total of 500 patients aged 59.4 (±10.2) years, with 9.9 (±6.7) years of diabetes duration (54% women, BMI: 29.6±5.1kg/m2) were analysed. The mean HbA1c was 8.3% (±1.9) and 34.2% of patients had a HbA1c level ≤7 %. 12%, 20% and 15.4% of diabetic patients were prescribed one, two or more than three antidiabetic drugs, 6.4% were on glucagon-like peptide 1 receptor agonists (GLP-1RA) only and 46% received insulin. Education level (OR=0.79; 95 % CI 0.66-0.94 p=0.009) and use of GLP-1RA (OR=0.19; 95 % CI 0.07-0.51 p=0.001) were associated with improved glycemic control while longer diabetes duration (OR=1.06; 95 % CI 1.02-1.11 p=0.004), use of basal insulin (OR=2.91; 95 % CI 1.70-6.88 p=0.010) and basal-prandial regiments (OR=2.49; CI 1.54-5.38 p=0.020) were associated with HbA1c >7%.
Conclusions: Despite the introduction of novel drugs in the treatment of T2DM a majority of our patients fail to reach therapeutic goals.
期刊介绍：
Acta Endocrinologica (Buc) is an international journal covering the fields of basic and clinical Endocrinology, Neuroendocrinology, Reproductive Medicine, Chronobiology, Human Ethology published quarterly
Acta Endocrinologica (Buc) is the official international journal of the Romanian Society for Endocrinology. It continues the former Romanian Journal of Endocrinology
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
